Brave new world revisited: Focus on nanomedicine

被引:14
|
作者
Fadeel, Bengt [1 ]
Alexiou, Christoph [2 ]
机构
[1] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, Nanomed & Nanosafety Lab NNL, S-17177 Stockholm, Sweden
[2] Univ Hosp Erlangen, Dept Otorhinolaryngol Head & Neck Surg, Sect Expt Oncol & Nanomed SEON, D-91054 Erlangen, Germany
基金
瑞典研究理事会;
关键词
Nanomedicine; Nanosafety; Theranostics; Oncology; Cardiovascular disease; IRON-OXIDE NANOPARTICLES; WALLED CARBON NANOTUBES; PROTEIN CORONA; DRUG-DELIVERY; SAFETY ASSESSMENT; CANCER; NANO; GOLD; BIODEGRADATION; SURFACE;
D O I
10.1016/j.bbrc.2020.08.046
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nanomedicine is at a crossroads: with relatively few success stories in terms of clinical translation despite more and more research on increasingly sophisticated nanomaterials, it is important to consider whether we are on the right track. Indeed, it is crucial that we address the fact that while considerable efforts are being made to overcome barriers to translation from the bench to the clinic, scientists are still struggling to decipher fundamental aspects of nanomaterial interactions with biological systems. We believe that a key to the successful adoption of nanomedicines in oncology and beyond lies in a deeper understanding of underlying biological processes and in decoding interactions between engineered nanomaterials and biological systems. Here we provide an overview of progress in nanomedicine during the past 5 years. (C) 2020 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:36 / 49
页数:14
相关论文
共 50 条